Dialysis industry news

Stories from the dialysis comunity across the globe.



Five-star: Where do we go from here? - NephrologyNews.com PDF Print

In the movie, “The Hundred Foot Journey,” Helen Mirren plays the owner of a French restaurant who has sought in vain to win the Michelin Star for her cuisine. Restaurants that win a star are listed in the Michelin Red Guide, a series of annual books published by the French company Michelin (yes, the tire maker) for more than one 100 years. The acquisition or loss of a star can have dramatic effects on the success of a restaurant.

We’re not sure the five-star rating system for dialysis providers will be around for 100 years, or whether it will have the same impact as the Michelin star does for restaurants. The five-star ratings went live Jan. 15 on the Dialysis Facility Compare website, and we haven’t heard about patients walking out en mass after discovering their clinics only had two stars. Likewise, we haven’t seen clinics boasting about their five-star ratings on billboards across the country.

That’s because the message about these ratings is still somewhat murky. What does a five-star rating really mean—or a two-star rating?

Make it simpler

The Centers for Medicare & Medicaid Services developed the star rating system for dialysis providers to accompany data on the DFC website, after determining that the raw data was too complex. The star ratings are based on that data, along with a few more quality measures added into the mix.

Star ratings and “compare” websites are not unique to dialysis; CMS has similar programs for nursing homes, home health agencies and, most recently, hospitals. Physicians are the next targets.

CMS says that the star ratings are part of Medicare’s efforts to make data easier to understand and for consumers to use. But here is where the explanatory language—located on the DFC website—gets a bit unclear for dialysis patients:

“The star ratings show whether your dialysis center provides quality dialysis care —that is, care known to get the best results for most dialysis patients. The rating ranges from 1 to 5 stars. A facility with a 5-star rating has quality of care that is considered 'much above average' compared to other dialysis facilities(emphasis added by author).

And, what if you are a one-or two-star facility?

A 1- or 2- star rating does not mean that you will receive poor care from a facility. It only indicates that measured outcomes were below average compared to those for other facilities.

The DFC website urges patients to “See how your facility compares to others based on star ratings.” And, “Talk to your doctors about the star ratings when you decided to get dialysis.”

So if I am a patient, should I tell my nephrologist that for my first dialysis treatment, I want to avoid any facility with two stars? “But Medicare says you will not receive poor care at the clinic I am recommending (which may also be a clinic that my practice group has a contract with and where I send most of my patients),” the nephrologist counters. “And it is the clinic closest to your home.”

CMS added the disclaimer that low stars do not’t mean poor care after the renal community howled over the implementation of the rating system. But pacifying dialysis providers may in fact make the significance of star ratings less clear for patients. If CMS tells me to “see how your facility compares to others based on star ratings,” but then says, “A 1- or 2- star rating does not mean that you will receive poor care from a facility,” it becomes confusing: Does a low star rating mean poor care – or not?

How stars shine

Our NN&I cover story last month by Mark Stephens  compared facilities with good performance scores in the Quality Incentive Program to the five-star rating. He found few similarities between the two. CMS counters that they are two separate evaluation systems and should not be compared.

I did a comparison of three dialysis clinics in my hometown of Scottsdale, Ariz. I picked a one star, three star, and a four-star clinic. All were within 20 miles of my location. 

All three clinics, according to CMS, have hospital admission and hospital readmission rates “as expected.” The three-star and four-star facilities also had mortality rates as expected. The one star clinic had a mortality rate “worse than expected,” according to the profile. But it’s not clear how much: if 1.00 is “as expected,” was this clinic 1.06? How "worse" is "worse"? The data isn’t provided.

Then the star rating system looks at clinical measures: Kt/V, the percentage of patients dialyzing with a fistula, and the number of patients with hypercalcemia (calcium >10.2 mg/dl). These quality measures are similar to what facilities must meet in the QIP.

In a side-by-side comparison of these three clinics, the four-star clinic did better in several categories—but not always by much.

• The one-star clinic had 94% of its patients with a Kt/V greater than 1.2; the four-star clinic had 95% of its patients hit that quality measure.

• Both the one-star and the four-star clinic had no patients with hypercalcemia.

But the one-star clinic had more patients with catheters (57% vs. 74%) and 26% of its patients still had catheters after 90 days (v. 9% for the four-star clinic). And that one-star clinic had a higher mortality rate, although we don’t know how much. So those differences in criteria made the difference in the star ratings.

Room for improvement

A special Technical Expert Panel met in late April to take a closer look at the rating system—another concession by CMS in response to the renal community’s displeasure with the system. Word is that the two-day meeting, organized by the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) under contract with CMS, produced some constructive debate. The panel was well represented by dialysis patient groups and providers, as well as experts in biostatistics. We’ll see if it leads to any changes.

Two things to consider: the Hospital Compare rating system does not use the “bell-shaped” curve formula that forces a set number of providers into each “star” rating. And hospitals can see their rating improved every three months based on how quality scores change. Currently, dialysis facilities have to wait a year before they can see their rating improve.

Let’s make it real

CMS’ goals are well intended with the star rating system: provide consumers with good information to help guide them in choosing a provider. The DFC site is well done and charts and graphs make it easy to make comparisons. But the star rating system was maligned from the first day it was presented, and forced on the renal community with little input on its methodology.

If it is to be a quality rating system, it needs to have the respect of those who it rates. Like the Michelin Star.  

...

 
Company Shares of DaVita healthCare Partners Inc. Drops by -1.38% - News Watch International PDF Print

DaVita healthCare Partners Inc. (NYSE:DVA) has lost 1.38% during the past week and dropped 0.1% in the last 4 weeks. The counter has underperformed the S&P 500 by 1.44% during the past week but DaVita healthCare Partners Inc. (NYSE:DVA) has outperformed the index in 4 weeks by 1.27%.

The company shares have rallied 15.02% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $85.17 and one year low was seen on June 18, 2014 at $69.83. The 50-day moving average is $82.62 and the 200 day moving average is recorded at $78.58. S&P 500 has rallied 8.07% during the last 52-weeks. Shares of DaVita healthCare Partners Inc. (NYSE:DVA) ended Friday session in red amid volatile trading. The shares closed down 0.79 points or 0.96% at $81.4 with 489,557 shares getting traded. Post opening the session at $81.74, the shares hit an intraday low of $81.31 and an intraday high of $82.14 and the price vacillated in this range throughout the day. The company has a market cap of $17,496 million and the number of outstanding shares has been calculated to be 214,941,000 shares. The 52-week high of DaVita healthCare Partners Inc. (NYSE:DVA) is $85.17 and the 52-week low is $69.83. 2.76% of the shares are held by the company Insiders, 83.6% of the shares are held by the institutions. Company shares has an average 3 month share volume of 933,220 and an average 10 day volume is recorded to be 749,188 DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysias Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
Kidney Disease Treatment Not For All in Uganda - Inter Press Service PDF Print
Africa, Editors' Choice, Education, Featured, Headlines, Health, Human Rights, Inequity, Poverty & SDGs, Projects Kidney Disease Treatment Not For All in Uganda - Inter Press Service

Patient undergoing dialysis treatment at Mulago Hospital in Kampala. Credit: Rebecca Vassie

KAMPALA, Jun 15 2015 (IPS) - Vincent Mugyenyi, a 65-year-old retired pilot from the Ugandan Air Force, has lost count of how many dialysis treatment slots he has had to attend in the eight years he has been fighting chronic kidney disease.

He spends eight hours a week on a dialysis machine in Mulago National Referral Hospital that filters toxins from his blood, performing the functions of healthy kidneys. The ultimate aim of dialysis is to bridge a gap until kidney functions recover or until a transplant is available for patients.

“I used to have a small farm with about one hundred animals. I sold all those animals for treatment because I still needed life. That is how this disease has affected me. It has depleted every resource of mine … land is very important but I have sold mine just to buy life,” Mugyenyi told IPS.

Mugyenyi is both luck and unfortunate. He is one of the minority of Ugandans with chronic kidney disease who has been able to receive dialysis treatment, but he does not qualify for a kidney transplant operation because of his advanced age.

“We don’t have sufficient data on the disease. We understand more about HIV, malaria and tuberculosis, because these are diseases with lots of funding behind them. But funding for kidney disease isn’t there. Kidney disease deserves the same level of importance as HIV” – Dr Robert Kalyesubula, nephrologist at Mulago Hospital in Kampala

Chronic kidney disease (CKD) is a growing health burden in Uganda that is affecting the economic, social and physical livelihoods of patients and their family members.

Dr, Simon Peter Eyoku, a kidney disease specialist at Mulago Hospital’s renal unit, told IPS that CKD affects mainly Ugandan adults aged between 20 and 50, and that the commonest causes of kidney diseases in Uganda are HIV-related infections of the kidney, followed by hypertension and diabetes.

The World Health Organisation (WHO) says that with CKD being the 12th leading cause of deaths worldwide and its incidence growing by around eight percent annually, it is a global public health concern.

Mulago National Referral Hospital is the only public hospital in Uganda treating patients with renal or kidney-related complications and, according to Eyoku, that often places a further burden on patients who have to travel long distances to the dialysis unit.

“I have seen patients migrate from far corners of the country to Kampala because that is where the dialysis machines are. That is how costly this disease can be to patients,” Eyoku told IPS.

A further problem is that the dialysis unit only has 33 haemodialysis machines for a total population of about 36 million people.

When the unit opened almost eight years ago with four dialysis machines, a patient had to pay the equivalent of 500 dollars for a week of dialysis treatment, making the cost of treatment prohibitive.

“Those who could afford it would fall out after selling land, houses, cars and then failing to continue. And at that time, the cost of a transplant was equal to the amount of money you paid in a year for dialysis,” said Eyoku.

In March 2014, the administration of Mulago Hospital decided to reallocate its budget in order to finance the renal unit and brought the cost of a week of treatment down to 40 dollars, but that is still out the reach of most Ugandans.

The hospital is now also offering two free sessions of dialysis, and Eyoku told IPS that this has led to an influx of patients with CKD, “so now we are struggling because we are getting many more patients on dialysis.”

Uganda’s health planners are accused of not giving priority to kidney-related diseases. “I wish we had more specialists managing kidney diseases,” Dr Robert Kalyesubula, one of the four consulting nephrologists at Mulago Hospital, told IPS.

“I wish we had more specialists managing kidney diseases, I wish we had more awareness programmes about kidney disease so that people know about it because it is devastating. I have seen big people break down on being diagnosed with kidney disease. And the pain, because it affects a whole family. If a father gets the disease then the children will not go to school.”

One of the difficulties with kidney disease is that in its early stages it has no specific symptoms so the patients who turn up for treatment are often in the final stages of the disease.

“Patients come in the dying stage,” said Kalyesubula. “You spend 90 percent of your time struggling to keep people alive rather than making them live.”

In addition, said the nephrologist, in Uganda as in the rest of sub-Saharan Africa, the magnitude of CKD is unknown and is not given sufficient importance.

“We don’t have sufficient data on the disease. We understand more about HIV, malaria and tuberculosis, because these are diseases with lots of funding behind them. But funding for kidney disease isn’t there. Kidney disease deserves the same level of importance as HIV. We are ignoring a disease which can be treated in its early stages.”

Patients who cannot afford to pay the 40 dollars a week for dialysis are treated in ward 4C, and the impression is that they are prisoners condemned to a death sentence with no possibility of appeal.

When IPS visits the ward on a busy afternoon, the scene was one of pathetic chaos, with the few doctors and nurses available rushing round, attending to both adult males and young girls in the same ward.

A male patient in his mid-forties had just died from kidney failure, and at the entrance to the ward, IPS met Rosemary Kyakuhaire, packing the bags of a brother who had died earlier in the day. She said that he had spent three weeks in the ward receiving palliative care because her family could not afford the expensive dialysis treatment.

In Uganda, Kalyesubula told IPS, a person would rather be diagnosed with HIV than kidney disease. “I say that mainly because HIV has a lot of support systems in Uganda. But for kidney disease, you are there on your own.  I have also seen people sell their houses to go for a kidney transplant but you don’t have to do that for HIV/AIDS.”

Provision of CKD treatment in Uganda depends primarily on whether the patient has health insurance or can otherwise afford treatment through taking out loans, selling property or financial support from relatives and friends. There are two private hospitals offering dialysis but only a lucky few can afford them.

Twenty-seven-year old Benon Mulindwa is one of the lucky ones. His employer, the Uganda People’s Defence Force (UPDF), had medical insurance cover for his treatment and transplant costs. He told IPS that without that medical cover, he could not have afforded the 20,000 dollars or so a year for dialysis and another 20,000 dollars for his kidney transplant.

However, Mulindwa received the transplant not in Uganda but in India, with his employer’s medical insurance cover paying for the costs of transport to India and surgery there. He explained that most patients have to look for their own kidney donors at home.

Unlike developed countries which run public kidney donation registries, patients in Uganda have to find potential donors and that, said Kalyesubula, is where one of the difficulties for CKD patients lies.

Because of lack of awareness about the safety of kidney donations, many Ugandans are unwilling to donate a kidney to save the life of one of the growing number of patients on the kidney donation waiting lists.

But that is not the only difficulty, as Mulindwa explained. “It is very difficult because there those who come as thieves, there those who come expecting to be paid a lot of money. I know of one who promised to donate a kidney to one of the patients, but when the money was sent the ‘donor’ disappeared.”

Edited byPhil Harris   

 

...

 
Company Shares of Rockwell Medical, Inc. Rally 10.82% - News Watch International PDF Print

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 10.82% in the past week and 32.8% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 10.75% and the outperformance increases to 34.62% for the last 4 weeks.

The company shares have rallied 18.51% in the past 52 Weeks. On June 12, 2015 The shares registered one year high of $13.35 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $10.74 and the 200 day moving average is recorded at $10.3. S&P 500 has rallied 8.07% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Friday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $13.23 and hit $13.35 on the upside , eventually ending the session at $13.32, with a gain of 1.76% or 0.23 points. The heightened volatility saw the trading volume jump to 419,890 shares. The 52-week high of the share price is $13.35 and the company has a market cap of $668 million. The 52-week low of the share price is at $8.095 . 18.55% of the shares are held by the company Insiders, 28% of the shares are held by the institutions. Company shares has an average 3 month share volume of 515,053 and an average 10 day volume is recorded to be 624,612 Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
Financial assistance for dialysis sought - The Hans India PDF Print
The Hans India
Dialysis needs to be performed for about 11 times in a month, it was being done eight times at MGM Hospital and the remaining were performed at private clinics, he told The Hans India. He informed that his father Parashuramulu committed suicide a

...

 
<< Start < Prev 161 162 163 164 165 166 167 168 169 170 Next > End >>

Page 162 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.